AU2017252344B2 - Diagnosis of immune_activation using CLEVER-1, TNF-alpha and HLA-DR binding agents - Google Patents

Diagnosis of immune_activation using CLEVER-1, TNF-alpha and HLA-DR binding agents Download PDF

Info

Publication number
AU2017252344B2
AU2017252344B2 AU2017252344A AU2017252344A AU2017252344B2 AU 2017252344 B2 AU2017252344 B2 AU 2017252344B2 AU 2017252344 A AU2017252344 A AU 2017252344A AU 2017252344 A AU2017252344 A AU 2017252344A AU 2017252344 B2 AU2017252344 B2 AU 2017252344B2
Authority
AU
Australia
Prior art keywords
macrophages
clever
gly
cys
hla
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017252344A
Other languages
English (en)
Other versions
AU2017252344A1 (en
Inventor
Maija-Leena HOLLMÉN
Markku Jalkanen
Mikael Maksimow
Miro VIITALA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Faron Pharmaceuticals Oy
Original Assignee
Faron Pharmaceuticals Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Faron Pharmaceuticals Oy filed Critical Faron Pharmaceuticals Oy
Publication of AU2017252344A1 publication Critical patent/AU2017252344A1/en
Application granted granted Critical
Publication of AU2017252344B2 publication Critical patent/AU2017252344B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/525—Tumor necrosis factor [TNF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70539—MHC-molecules, e.g. HLA-molecules
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • G01N2333/7151—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF]; for lymphotoxin [LT]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AU2017252344A 2016-04-18 2017-04-18 Diagnosis of immune_activation using CLEVER-1, TNF-alpha and HLA-DR binding agents Active AU2017252344B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FI20165336 2016-04-18
FI20165336 2016-04-18
PCT/FI2017/050286 WO2017182706A1 (en) 2016-04-18 2017-04-18 Diagnosis of immune_activation using clever-1, tnf-alpha and hla-dr binding agents

Publications (2)

Publication Number Publication Date
AU2017252344A1 AU2017252344A1 (en) 2018-10-11
AU2017252344B2 true AU2017252344B2 (en) 2023-12-21

Family

ID=58692521

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017252344A Active AU2017252344B2 (en) 2016-04-18 2017-04-18 Diagnosis of immune_activation using CLEVER-1, TNF-alpha and HLA-DR binding agents

Country Status (10)

Country Link
US (1) US10884000B2 (enExample)
EP (1) EP3445786B1 (enExample)
JP (2) JP7100588B2 (enExample)
KR (1) KR102403660B1 (enExample)
CN (1) CN109153720B (enExample)
AU (1) AU2017252344B2 (enExample)
BR (1) BR112018070350A2 (enExample)
CA (1) CA3020418A1 (enExample)
EA (1) EA201892313A1 (enExample)
WO (1) WO2017182706A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3113895A1 (en) 2018-11-01 2020-05-07 Faron Pharmaceuticals Oy Tlr9 agonists for use in downregulating clever-1 expression on alternatively activated macrophages
US20220404366A1 (en) * 2019-11-11 2022-12-22 Faron Pharmaceuticals Oy Anti-clever-1 agents for controlling the expression of cell surface markers on leucocytes, and using these to guide anti-clever-1 based cancer treatment
CA3174858A1 (en) * 2020-04-20 2021-10-28 Juho JALKANEN Treatment of diseases with clever-1 inhibition in combination with an interleukin inhibitor
US20220227858A1 (en) 2021-01-18 2022-07-21 Faron Pharmaceuticals Oy Controlling of immune activation by soluble clever-1
WO2023105118A1 (en) * 2021-12-07 2023-06-15 Faron Pharmaceuticals Oy Method for using inflammatory markers to guide anti-clever-1 cancer treatment

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003057130A2 (en) * 2002-01-09 2003-07-17 Sirpa Jalkanen Common lymphatic endothelial and vascular endothelial receptor-1 (clever-1) and uses thereof
FI20090161A0 (fi) * 2009-04-22 2009-04-22 Faron Pharmaceuticals Oy Uusi solu ja siihen pohjautuvia terapeuttisia ja diagnostisia menetelmiä
CN104936983A (zh) 2012-11-09 2015-09-23 特朗斯吉有限公司 对单核细胞或其前体分化的调节
BR112015032690B1 (pt) 2013-06-25 2020-03-10 Vaccinex, Inc. Uso de moléculas inibidoras de semaforina-4d em combinação com uma terapia imunomoduladora para inibir o crescimento tumoral e metástase

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
PALANI, S. ET AL.: "Monocyte stabilin-1 suppresses the activation of Th1 lymphocytes", J IMMUNOL, vol. 196, no. 1, JPN6020048518, 1 January 2016 (2016-01-01), pages 115 - 123, XP055706096, ISSN: 0004409255, DOI: 10.4049/jimmunol.1500257 *
SENTHIL PALANI: "CLEVER-1 AS AN IMMUNE SUPPRESSIVE MOLECULE", UNIVERSITY OF TURKU, 18 March 2016 (2016-03-18), pages 1 - 72, XP055384491, ISBN: 978-951-29-6409-3, Retrieved from the Internet [retrieved on 20170623] *

Also Published As

Publication number Publication date
JP7100588B2 (ja) 2022-07-13
WO2017182706A1 (en) 2017-10-26
EP3445786B1 (en) 2023-10-04
US10884000B2 (en) 2021-01-05
KR102403660B1 (ko) 2022-05-30
JP7302049B2 (ja) 2023-07-03
US20190064180A1 (en) 2019-02-28
CN109153720A (zh) 2019-01-04
KR20180133854A (ko) 2018-12-17
JP2019521312A (ja) 2019-07-25
AU2017252344A1 (en) 2018-10-11
EA201892313A1 (ru) 2019-03-29
CA3020418A1 (en) 2017-10-26
BR112018070350A2 (pt) 2019-01-29
EP3445786C0 (en) 2023-10-04
CN109153720B (zh) 2022-10-21
JP2022065088A (ja) 2022-04-26
EP3445786A1 (en) 2019-02-27

Similar Documents

Publication Publication Date Title
AU2017252344B2 (en) Diagnosis of immune_activation using CLEVER-1, TNF-alpha and HLA-DR binding agents
US20200093924A1 (en) Selective targeting of the cd40l/mac-1 interaction by small peptide inhibitors and its use for the treatment of inflammation and atherogenesis
JP6682438B2 (ja) 癌治療のための改善された細胞組成物および方法
KR20150143625A (ko) 신데칸 2의 의학적 용도
JP2002504334A (ja) Ｏｘ−４０レセプター結合因子又はそれをコードする核酸を含む組成物並びに抗原特異的免疫応答を増強するための方法
TWI847958B (zh) 用精胺酸耗盡劑進行之組合癌症免疫療法
JP2023071898A (ja) ＣＤ３００ｃの発現抑制剤または活性抑制剤を含む癌の予防または治療用薬学的組成物
JP2004505927A (ja) 乾癬及び他の炎症性皮膚状態の治療用ｃｄ４０アンタゴニスト
WO1996011700A1 (en) Reduction of mammalian neoplasms with phospholipase a2 activatiing substances
HK1261998B (en) Diagnosis of immune activation using clever-1, tnf-alpha and hla-dr binding agents
HK1261998A1 (en) Diagnosis of immune activation using clever-1, tnf-alpha and hla-dr binding agents
CN110139659B (zh) 用于治疗干燥综合征的肽
CA2906597A1 (en) Enhancement of vaccines
WO2023167033A1 (ja) プロレニン受容体ペプチド、コンジュゲート、および医薬組成物
JPH08225462A (ja) ワクチン
HK40012327A (en) Peptides for treating sjogren's syndrome
WO2017142988A1 (en) Methods and compositions for treating melanoma
EA043588B1 (ru) Лекарственное средство, содержащее рекомбинантные лектины омелы, для лечения опухолей головного мозга
HK1178935A1 (zh) 含增强免疫应答的fc融合蛋白的方法和组合物
HK1178935B (en) Methods and compositions containing fc fusion proteins for enhancing immune responses
HK1188123B (en) Selective targeting of the cd40l/mac-1 interaction by small peptide inhibitors and its use for the treatment of inflammation and atherogenesis
HK1188123A (en) Selective targeting of the cd40l/mac-1 interaction by small peptide inhibitors and its use for the treatment of inflammation and atherogenesis

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)